Virtual Investor Event
Join Hansa Biopharma for an investor event featuring two KOLs discussing unmet need and current treatment landscape for Guillain-Barré syndrome (GBS).
June 16, 14:00 CEST/8:00 AM ET
Register and attend
Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative immunomodulatory treatments for people living with rare immunological conditions.
Founded in 2007 and based in Lund, Sweden, Hansa is a biopharma company with a growing presence in Europe and the US. The company is listed on the Nasdaq Stockholm.
Years of innovation
Clinical and preclinical programs
Nationalities represented in our workforce
is a world where all patients with rare immunologic diseases can lead long and healthy lives.
is to leverage our unique immunomodulating technology platform to develop innovative, lifesaving and life altering therapies, ensure fair and equitable access to these medicines, and generate value to society at large.
Hansa has developed a proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease-causing IgG antibodies.
Imlifidase is a first-generation enzyme designed to rapidly and specifically inactivate IgG antibodies in plasma and tissues through a single intravenous treatment.
HNSA-5487 is a next-generation enzyme that could potentially expand the IgG-free window through short-term repeat dosing.
We are currently evaluating our enzymes across a wide spectrum of disease areas and indications in an effort to address significant unmet medical needs.
Sustainability is considered an important part of Hansa’s business. We are committed to advancing science in areas of high unmet need and ensuring access to new medicines for patients and clinicians. We take an agile approach to Sustainability – evolving the strategy and priority areas of focus over time and in line with the Company’s growth.
Our ability to advance science and deliver innovative new medicines is grounded in a culture that values authentic, transparent communication and encourages an inclusive and diverse workplace. Being authentic and feeling empowered to speak up remains a top priority for the Company.
At Hansa Biopharma, we strive to create an inclusive environment that embraces difference and fosters inclusion. We believe that valuing diversity and inclusion will create an environment in which all talent can grow and our employees can thrive, and we are fully committed to ensuring our employees are treated equally, regardless of their ethnicity, sex, religion, disability, age, sexual orientation, gender identity or expression.
We value and promote equality and inclusion in our workforce and across our global leadership. To ensure our board is inclusive, we have implemented a board diversity policy, which outlines a required blend of geographical and cultural backgrounds, professional experiences, and knowledge, including gender balance.
To specifically ensure gender equality at Hansa, we conduct yearly salary surveys to ensure that men and women receive equal pay for equivalent work.